miR-222 exerts negative regulation on insulin signaling pathway in 3T3-L1 adipocytes.
Pere BibiloniCatalina Amadora PomarCatalina PicóJuana SánchezFrancisca SerraPublished in: BioFactors (Oxford, England) (2022)
Increased miR-222 levels are associated with metabolic syndrome, insulin resistance, and diabetes. Moreover, rats fed an obesogenic diet during lactation have higher miR-222 content in breast milk and the offspring display greater body fat mass and impaired insulin sensitivity in adulthood. In order to investigate the molecular mechanisms involved and to dissect the specific effects of miR-222 on adipocytes, transfection with a mimic or an inhibitor of miR-222 has been conducted on 3T3-L1 preadipocytes. 3T3-L1 cells were transfected with either a mimic or an inhibitor of miR-222 and collected after 2 days (preadipocytes) or 8 days (mature adipocytes) for transcriptomic analysis. Results showed a relevant impact on pathways associated with insulin signaling, lipid metabolism and adipogenesis. Outcomes in key genes and proteins were further analyzed with quantitative reverse transcription polymerase chain reaction and Western Blotting, respectively, which displayed a general inhibition in important effectors of the identified routes under miR-222 mimic treatment in preadipocytes. Although to a lesser extent, this overall signature was maintained in differentiated adipocytes. Altogether, miR-222 exerts a direct effect in metabolic pathways of 3T3-L1 adipocytes that are relevant to adipocyte function, limiting adipogenesis and insulin signaling pathways, offering a mechanistic explanation for its reported association with metabolic diseases.
Keyphrases
- cell proliferation
- long non coding rna
- long noncoding rna
- adipose tissue
- type diabetes
- insulin resistance
- signaling pathway
- metabolic syndrome
- high fat diet induced
- pi k akt
- glycemic control
- high fat diet
- physical activity
- oxidative stress
- depressive symptoms
- fatty acid
- skeletal muscle
- mass spectrometry
- epithelial mesenchymal transition
- smoking cessation
- cell cycle arrest
- weight loss
- polycystic ovary syndrome
- combination therapy